Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults

NCT ID: NCT01620567

Last Updated: 2019-07-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognitive impairment is also a major risk factor for development of dementia later in life. Findings from the investigators studies suggest that the carotenoids, lutein and zeaxanthin may be important in cognitive function in the elderly. Avocados are a source of these carotenoids. The investigators study evaluates long-term avocado intervention as a treatment strategy for age-related cognitive impairment which could possibly prevent the onset of dementia. The investigators have also shown that lutein supplementation significantly improved verbal fluency scores in healthy older women. Based on these findings, the next logical step will be to investigate the ability of lutein and zeaxanthin contained in avocados to influence cognitive function in older adults. The investigators hypothesize that there will be a significant increase in cognitive function measures in older adults provided with meals containing 1 avocado/day at the end of 6 months, while no significant improvements will be observed in older adults given daily meals containing chickpeas and/or potatoes.

The proposed study is designed as a randomized, placebo controlled trial that tests the effects of 6 month supplementation with 1 avocado/day on cognitive function in older adults. Secondary analyses will determine whether baseline macular pigment (lutein in retina which canbe measured non invasivley) density predicts relative effectiveness of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of oxidative stress and inflammation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed as a placebo controlled trial that tests the effects of 6 month supplementation with daily meals containing 1 avocado or isocaloric amounts of chickpeas and/or potatoes on cognitive function in older adults. Subjects will be randomly assigned to one of the two groups. Secondary analyses will determine whether baseline macular pigment density (a non invasive measure of lutein and zeaxanthin in neural tissue) predicts relative effectiveness of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of oxidative stress and inflammation. Participants will be recruited from community-dwelling men and women aged \>50 yr, and potential participants will be screened to meet cognitive and functional criteria. Participants will be pre-screened by telephone; those who appear to meet criteria will undergo further screening. The study will include baseline (0 month), 3 and 6 month visits for study procedures, and monthly telephone calls. Given that there is a visible difference between the two interventions, a blinded study is not possible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chickpeas/potatoes

1 potato/day or 1 cup chickpeas

Group Type PLACEBO_COMPARATOR

potato or chickpea

Intervention Type OTHER

1 cup potatoes or chickpeas/day for 6 months

avocados

1 avocados/day

Group Type ACTIVE_COMPARATOR

avocado

Intervention Type OTHER

1 avocado/day for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

avocado

1 avocado/day for 6 months

Intervention Type OTHER

potato or chickpea

1 cup potatoes or chickpeas/day for 6 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men and women age \> 50 years
* BMI 19-30 kg/m2
* lutein intake of \< 3 mg/d
* Docosahexaenoic acid intake \< 250 mg/d (including supplements)
* Mini mental state exam (MMSE) score \> 24
* Macular pigment density \< 0.4 at 0.5 degrees
* Beck Depression Inventory \< 20
* free of known disease
* BMI 19-29 kg/m2
* must be able to give written informed consent
* have normal hematologic parameters
* normal values of plasma albumin
* normal values for liver and kidney function (Appendix A)
* no use of carotenoid, n3 fatty acid, multivitamin/mineral, (\> 2 months).

Exclusion Criteria

* history of active small bowel disease or resection
* atrophic gastritis
* hyperlipidemia (LDL \>120 mg/dL or triglycerides \>150 mg/dL)
* hypertension (\>150/90 mm Hg)
* diabetes, alcoholism (\>2 drinks/d or 14 drinks/week)
* pancreatic disease
* anemia, and bleeding disorders (as determined by screening interview)
* avocado, potato or chickpea allergy
* pregnancy or lactation
* diseases that interfere with fat absorption, e.g. colitis, celiac disease, Crohn's disease, cystic fibroids (as determined by screening interview)
* medications that interfere with fat absorption, e.g. bile sequestrants (as determined by screening interview)
* use of antipsychotic, antimanic, anti-inflammatory, monoamine inhibitors, or dementia medications
* smoking or use of nicotine patches or gum (within past 6 months)
* use of drugs suspected of interfering with metabolism of blood clotting, e.g. warfarin (as determined by screening interview)
* subjects having extremely high dietary intakes of carotenoids as indicated by screening plasma values \> NHANES 95th percentile for lutein/zeaxanthin, beta-carotene, cryptoxanthin, or lycopene
* stroke,head injury with loss of consciousness or seizures.
* Non English speaking: This is a small study with a sample size. Logistically and financially, getting materials translated for such a small study is not feasible.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tufts University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elizabeth J Johnson, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tufts University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cognitive Effects of Bioavailable Curcumin
NCT07251985 NOT_YET_RECRUITING PHASE2
Snacks and Brain Health
NCT07348406 NOT_YET_RECRUITING PHASE1/PHASE2
Walnuts and Healthy Aging
NCT01634841 COMPLETED NA